Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer

This study has been terminated.
(Financing and re-organization)
Sponsor:
Information provided by (Responsible Party):
Galectin Therapeutics Inc.
ClinicalTrials.gov Identifier:
NCT00388700
First received: October 13, 2006
Last updated: August 13, 2014
Last verified: August 2014
  Purpose

The purpose of this clinical trial is to determine whether the combination of 5-fluorouracil (5-FU) plus a DAVANAT (carbohydrate polymer) along with Avastin and Leucovorin (LV) is beneficial in treating colorectal cancer in patients unable to tolerate intensive chemotherapy.


Condition Intervention Phase
Colorectal Cancer
Drug: GM-CT-01
Drug: 5-Fluorouracil, Leukovorin, bevacizumab
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open-Label, Phase 2 Study of GM-CT-01 When Added to a Regimen of Leucovorin, 5-FU, and Avastin as First Line Treatment for Locally Advanced, Unresectable or Metastatic Colorectal Cancer in Subjects Unable to Tolerate Intensive Chemotherapy

Resource links provided by NLM:


Further study details as provided by Galectin Therapeutics Inc.:

Primary Outcome Measures:
  • Primary Outcomes: Assess the efficacy and safety of GM-CT-01 administered with 5-FU, LV, and Avastin® in the first-line treatment of unresectable, locally advanced, and/or metastatic CRC. [ Time Frame: When 17 evaluable patients will complete the study ] [ Designated as safety issue: Yes ]
    To assess the clinical benefit of a regimen of GM-CT-01/5-FU, LV plus Avastin® when administered intravenously as a first-line treatment to patients with Stage III or IV ,advanced or metastatic CRC. Clinical activity will be assessed by determining the percentage of subjects exhibiting an objective response (complete response [CR]) plus partial response [PR]). Tumor response will be assessed following Response Evaluation by RECIST guidelines.


Secondary Outcome Measures:
  • To evaluate the safety of the DAVANAT®/5-FU, LV plus Avastin® regimen. [ Time Frame: Throughout the study and when 17 evaluable patients will when complete the study ] [ Designated as safety issue: Yes ]
    Assess safety of regimen and also patient reported outcomes using a Quality of Life (QoL) instrument.

  • Explore progression-free survival (PFS) and survival [ Time Frame: When at least 17 evaluable patients complete the study ] [ Designated as safety issue: No ]
    To explore time to tumor progression, duration of response and and survival at 6 and 12 months after the first dose of study drug.


Enrollment: 10
Study Start Date: October 2006
Study Completion Date: June 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: GM-CT-01
    On Day 1 and 2 of each cycle, GM-CT-01 280 mg/m2 administered IV over 30 minutes with 5-FU (400 mg/m2), followed by a 22-hour continuous infusion of GM-CT-01 (280 mg/m2) with 5-FU (600 mg/m2 .)
    Other Name: DAVANAT
    Drug: 5-Fluorouracil, Leukovorin, bevacizumab
    On Day 1 and 2 of each cycle, LV (200 mg/m2) will be administered IV over 2 hours, followed by 5-FU 400 mg/m2 in solution with GM-CT-01 280 mg/m2 administered over 30 minutes, followed by a 22-hour continuous infusion of GM-CT-01 (280 mg/m2) and 5-FU (600 mg/m2 ). on Day 3 Avastin® (5 mg/kg)will be given IV over 30 to 90 minutes per the package insert.
    Other Name: 5-FU, LV, Avastin®
Detailed Description:

This is a Phase II, multi-center study of DAVANAT which has been shown to increase the anti-tumor activity of 5-FU in mice. 5-FU is a chemotherapy drug commonly used to treat tumors. A Phase I study of 40 patients showed that DAVANAT in different doses plus 5-FU was well tolerated in patients with different types of solid tumors who failed standard, approved treatments.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years or older.
  • Histologically confirmed, unresectable, locally advanced or metastatic colorectal adenocarcinoma (stage III and IV), not amenable to curative surgery or radiotherapy.
  • Intolerant of oxaliplatin and/or irinotecan, as demonstrated by unacceptable toxicity after a trial of these agents as first-line therapy, or in the opinion of the Investigator, be judged at high risk for unacceptable toxicity to oxaliplatin and/or irinotecan,
  • Presence of at least 1 measurable lesion,
  • Have a life expectancy of at least 4 months.
  • Women of childbearing potential, have a negative serum pregnancy test at screening and Day 1 treatment and agree to practice abstinence or use an effective method of contraception.

Exclusion Criteria:

  • Central nervous system metastasis.
  • Bony metastasis as the sole metastasis.
  • Received any prior first-line chemotherapy for colorectal cancer.
  • Previously exposed to DAVANAT® or Avastin®.
  • Known or clinically suspected infection with HIV.
  • Participated within 30 days or will participate concurrently in another investigational drug or vaccine study.
  • History of drug or alcohol dependence in the past 3 years.
  • Other serious, non-malignant, significant, acute or chronic medical or psychiatric illness that in the judgment of the Investigator could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00388700

Locations
Israel
Rambam Medical Center
Haifa, Israel, 31096
Kaplan MC
Rechovot, Israel
Sheba MC
Tel Hashomer, Israel, 52621
Sourasky Medical Center
Tel-Aviv, Israel, 64239
Sponsors and Collaborators
Galectin Therapeutics Inc.
  More Information

No publications provided

Responsible Party: Galectin Therapeutics Inc.
ClinicalTrials.gov Identifier: NCT00388700     History of Changes
Other Study ID Numbers: DAVFU006
Study First Received: October 13, 2006
Last Updated: August 13, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Galectin Therapeutics Inc.:
Colorectal cancer, DAVANAT, colon cancer, 5-FU

Additional relevant MeSH terms:
Colorectal Neoplasms
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms
Neoplasms by Site
Rectal Diseases
Bevacizumab
Fluorouracil
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on November 24, 2014